Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00622869 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 719
- Enrollment target
NCT00622869 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 719 participants.
The verdict
NCT00622869, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 719 participants
- Enrollment target
Study Summary
This trial was designed to address important issues that impact recipients of liver allografts as well as clinicians, ie, renal function, reduction or discontinuation of tacrolimus early post-transplantation, and progression rate of fibrosis in hepatitis C virus (HCV) positive patients.
Interventions
- DRUG Tacrolimus (reduced tacrolimus)
- DRUG Everolimus (reduced tacrolimus)
- DRUG Tacrolimus (tacrolimus elimination)
- DRUG Everolimus (tacrolimus elimination)
- DRUG Tacrolimus (tacrolimus control)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 719 participants |
| Start Date | 2008-01 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00622869
The ClinicalTrials.gov registry entry for NCT00622869 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 719 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Tacrolimus (reduced tacrolimus) is the first listed.
NCT00622869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00622869 about?
NCT00622869 is a clinical study titled "Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients". This trial was designed to address important issues that impact recipients of liver allografts as well as clinicians, ie, renal function, reduction or discontinuation of tacrolimus early post-transplantation, and progression rate of fibrosis in hepatitis C virus (HCV) positive patients.
What is the current status of trial NCT00622869?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 719 participants. The study started on 2008-01. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00622869?
The interventions under investigation include: Tacrolimus (reduced tacrolimus) (DRUG), Everolimus (reduced tacrolimus) (DRUG), Tacrolimus (tacrolimus elimination) (DRUG), Everolimus (tacrolimus elimination) (DRUG), Tacrolimus (tacrolimus control) (DRUG).
Who is sponsoring clinical trial NCT00622869?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.